Results 61 to 70 of about 6,313 (204)

Ciproxifan, an H~3~ Receptor Antagonist, Improves Learning and Memory in the APP Mouse Model of Alzheimer's Disease [PDF]

, 2009
Mice that express the mutant form of the human amyloid precursor gene associated with early-onset familial Alzheimer's disease demonstrate memory deficits and amyloid plaques.
Mark E. Bardgett, Molly S. Griffith, Natasha N. Davis   +2 more
core   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Cellular distribution of the histamine H3 receptor in the basal ganglia : functional modulation of dopamine and glutamate neurotransmission [PDF]

, 2013
This is the author's version of a work that was accepted for publication in Basal ganglia. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be ...
Castillo Ruiz, Mª del Mar, Díaz, Jorge, González Sepúlveda, Marta, Hoffmann, Hanne Mette, Mignon, Virginie, Moreno Delgado, David, Ortiz de Pablo, Jordi, Rosell Vilar, Santi, Sabrià i Pau, Josefa, Vignes, Michel   +9 more
core   +2 more sources

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, Volume 183, Issue 7, Page 1364-1389, April 2026.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Effects of MP-AzeFlu enhanced by activation of bitter taste receptor TAS2R

Allergy, Asthma & Clinical Immunology, 2020
MP-AzeFlu is relatively new a pharmaceutical drug used in the treatment of allergic rhinitis. It is comprised of azelastine hydrochloride (AZE), a potent histamine-H1-receptor antagonist and fluticasone propionate (FP), corticosteroid.
Sandra Ekstedt, Susanna Kumlien Georén, Lars Olaf Cardell   +2 more
doaj   +1 more source

Cytokine responses of intraepithelial lymphocytes are regulated by histamine H2 receptor [PDF]

, 2009
Backgrounds. Histamine participates in the immune regulation of several gastrointestinal diseases. However, the effect of histamine on intestinal intraepithelial lymphocytes (IELs), the front line of intestinal mucosal immune system, is not well ...
A Di Sabatino, A Hayday, A Mazzoni, Akira Hishida, B Lagier, C Lundqvist, CA Akdis, CA Akdis, CC Fox, D Montufar-Solis, E Bolton, E Masini, G Barbara, G Caron, G Monteleone, H Cheroutre, H Cheroutre, H Kiyono, HD Lim, HK Takahashi, IJ Elenkov, K Hoshino, K Takahashi, K Tomita, Kosuke Takagaki, L Knutson, L Lefrancois, LB Hough, LB Svendsen, LE Sander, M Jutel, M Kawaguchi, M Watanabe, Mutsuhiro Ikuma, N Osna, N Osna, P Parronchi, R Boismenu, R Leurs, RL Mosley, S Bischoff, S Kapoor, S Matsumoto, S Takamatsu, S Winterkamp, Satoshi Osawa, T Morichika, T Taguchi, T Taguchi, TA Barrett, Takahisa Furuta, Takanori Yamada, WJ Adams, WJ Adams, Y Horio, Y Sonobe, Yasuhiro Takayanagi, Yasushi Hamaya, Yoshiaki Horio   +58 more
core   +1 more source

Monoaminylation in Human Health and Disease: State of the Field, Challenges, and Emerging Directions

Advanced Science, Volume 13, Issue 16, 18 March 2026.
This review delineates monoaminylation—serotonylation, dopaminylation, and histaminylation—as key post‐translational modifications beyond receptor signaling. It details their catalytic mechanisms, roles in gene expression and protein function, and implications in health and disease, aiming to bridge mechanistic insights with therapeutic potential ...
Yiqi Zhao, Hongli Zhang, Yating Yang, Wei‐Dong Chen, Yan‐Dong Wang   +4 more
wiley   +1 more source

H3 antagonists and postoperative cognitive dysfunction

Journal of Anaesthesiology Clinical Pharmacology, 2019
Since histamine (HA) was first synthesized in 1907 and isolated as a bacterial contaminant of an extract of ergot in 1910, its role in health and disease and its molecular mechanism of action have been unraveled, leading to the formulation of an array of
Chandrasekhar Krishnamurti
doaj   +1 more source

Sizing up pharmacotherapy for obesity. [PDF]

, 2010
Obesity has increased over the last 20 years, from a condition affecting only a small portion of populations in developed countries, into a global pandemic.
Terzic, Andre, Valentino, Michael A., Waldman, Scott A.   +2 more
core   +2 more sources

Binding of histamine H₃‐receptor antagonists to hematopoietic progenitor cells [PDF]

FEBS Letters, 1997
© 1997 Federation of European Biochemical Societies.
Corbel, Stéphane, Traiffort, Elisabeth, Stark, Holger, Schunack, Walter, Dy, Michel   +4 more
openaire   +2 more sources